Public Citizen is pushing the FDA to take Crestor (rosuvastatin) off the market

April 2004

The consumer group, Public Citizen, is pushing the FDA to take Crestor (rosuvastatin) off the market.

They say that rates of renal failure and rhabdo are too high.

Public Citizen has a track record worth noting. They successfully went after phenylpropanolamine, Rezulin, Trovan.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

whether cholesterol needs to go even lower than previously thought for unstable heart disease patients
Cholesterol Public Citizen is pushing the FDA to take Crestor (rosuvastatin) off the market
what works for nighttime leg cramps
Some antipsychotics seem to increase the risk of stroke in elderly patients with dementia
Dermatology Many women on Accutane are still getting pregnant
Dermatology best treatment for toenail fungus
Infectious Diseases Suprax (cefixime) will be coming back onto the market
Men's Health using testosterone for "male menopause"
Hematology & Oncology More women with breast cancer will be switched from tamoxifen to an aromatase inhibitor
whether coenzyme Q10 should be recommended for patients taking statins
Cardiology Caduet (KA-doo-et), a combination of Lipitor and Norvasc
Women's Health the risks for women taking estrogen (Premarin) ALONE
Women's Health which home pregnancy test is best
Diabetes & Endocrinology Sensipar, a new drug for dialysis patients
Spiriva, a new bronchodilator for chronic obstructive pulmonary disease